PD-L1-specific T cells
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cancer Immunology, Immunotherapy |
Vol/bind | 65 |
Udgave nummer | 7 |
Sider (fra-til) | 797-804 |
Antal sider | 8 |
ISSN | 0340-7004 |
DOI | |
Status | Udgivet - jul. 2016 |
ID: 168909559